Third Price-Fixing Lawsuit Filed In US

Major Topicals Players Named Include Sandoz, Actavis, Mylan And Perrigo

A third major price-fixing lawsuit has been filed in the US, naming over two dozen companies and ten individuals in allegations covering 80 generic presentations, focusing in particular on topical drugs.

Handshake
A series of price-fixing arrangements are alleged in the filing • Source: Shutterstock

A coalition of 51 US states and territories has come together to file a third major lawsuit over generic price-fixing in the US, naming over two dozen companies and ten individuals in a complaint that covers 80 generic presentations.

The 606-page lawsuit focuses particularly on generic topicals and names 26 corporate defendants, including Sandoz, Teva’s Actavis, Mylan, Amneal,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin